Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-MILL-DELG-1209009655
Principal InvestigatorDelgado, David
PhasePhase I
Age GroupChildren
TitleA phase I study evaluating the addition of bortezomib to an established acute graft versus host disease (aGVHD) prophylaxis regimen in pediatric allogeneic hematopoietic stem cell transplant (alloHSCT) patients
DescriptionThe objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with cyclosporine and methotrexate as acuite graft versus host disease (aGVHD) prophylaxis in pediatric patients undergoing allogeniec hematopoietic stem cell transplant (alloHSCT)
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Subjects must be greater than or equal to 1 years old and less 22 years old
  • Subjects must have any malignant or non-malignant condition that requires treatment with alloHSCT
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Methodist Healthcare
  • Methodist Children's Hospital
Treatment TypeTreatment
ContactAnne Bubnick, Phone: